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MEP molecular electrostatic potential
MF268 8-(cis-2,6-dimethylmorpholino)octylcarbamoyleseroline  
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NDDO neglect of diatomic differential overlap
PAS peripheral anionic site
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QM quantum mechanics
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t   half-life for esteratic hydrolysis
1molecular formula, see page vii
v


















































Molecular modeling is the science or art of representing molecular structures nu-
merically and simulating their behavior with the equations of quantum and clas-
sical physics and it is one of the fastest growing fields in science. The modeling
techniques are widespread in their uses and have become more and more impor-
tant in widely varying fields of chemistry, ranging from small organic molecules
to proteins, polymers, inorganic solids, and liquids. Molecular modeling varies
from building, visualizing and comparing molecules to performing complicated
and time demanding calculations on rather big molecular systems. As with all
models, however, the intuition and training of the chemist is necessary to interpret
the results appropriately. Comparison to experimental data, where available, is
important to guide both laboratory and computational work.
1.2 The prodrug concept
The discovery and development of a new drug is often a complicated, expensive
and long process. Traditionally a known active lead molecule has been used as
a template structure in modifying a new active drug. Nevertheless, the develop-
ment of computer-aided drug design can now provide us with very specific and
potent drug molecules. However, the physicochemical properties of the new drug
candidates may be unfavorable. Solubility and stability have a significant effect
on the pharmaceutical and biopharmaceutical behavior of the drug molecule. The
physicochemical properties need to be determined and optimized during the de-
velopment of the drug.
A prodrug is an inactive derivative of a drug molecule that requires chemical or
biological transformation in vivo in order to release the active substance. The
purpose of a prodrug can be to increase or decrease water/lipid solubility and the
metabolic stability of a drug, interfere with its transport characteristics, mask side
effects or toxicity or only improve the flavor of the drug. Prodrug-technology can
be applied to all drug administration routes and dosage forms. The ultimate goal
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in prodrug design is however to achieve target organ selectivity and/or prolonged
duration of therapeutic effects.
Certain disadvantages of prodrug molecules, for example stability problems can
be overcome by the double prodrug concept [1], i.e. making a prodrug from a
prodrug.
A variety of novel pilocarpine prodrugs in the form of different pilocarpic acid
esters, bispilocarpic acid monoesters and bispilocarpic acid diesters have been
synthesized and thoroughly investigated by T. Järvinen et al. at the University
of Kuopio [2]. The ideal ocular prodrug should be sufficiently lipophilic in the
purpose of penetrating the corneal membrane. In addition, the prodrug should
be stable in aqueous solutions, non-toxic, non-irritative and it should release the
active substance, in this case pilocarpine, within the eye at a controlled rate. The
experimental development of pilocarpine prodrugs, by the Kuopio group has fo-
cused on enhancing the lipophilic character needed for an effective penetration
of the corneal membrane. By using molecular modeling various physicochemical
properties of the pilocarpine prodrugs could be illustrated and differentiated.
1.3 Biological data of acetylcholinesterase and butyrylcholin-
esterase
In vertebrates, two types of cholinesterases can be distinguished on the basis of
their substrate and inhibitor sensitivity. Acetylcholinesterase (AChE, E.C 3.1.1.7),
which is predominantly present in the central and peripheral nervous system and in
skeletal muscles, causes the termination of impulse transmission by rapid hydrol-
ysis of acetylcholine to yield acetic acid and choline [3]. Butyrylcholinesterase
(BChE, E.C 3.1.1.8) is primarily synthesized in the liver and secreted into the
plasma and it also hydrolyzes acetylcholine, but as yet has no known physiologi-
cal function. During embryonic development a pattern of organization or succes-
sion of BChE and AChE has been reported, leading to the hypothesis that BChE
functions as an embryonic AChE [4, 5]. Although the catalytic function of AChE
is clear, its quaternary organization is surprisingly complex and is still not entirely
elucidated - it exists in a large variety of molecular forms that all possess the same
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catalytic activity in a given species.
Both AChE and BChE exist as polymers of catalytic subunits. The globular forms
G1, G2 and G4 contain one, two or four subunits. The forms can be classified as
either hydrophilic, secreted into body fluids or amphiphilic, tightly bound to cell
membranes [6].
There is a high degree of similarity between Torpedo californica AChE (TcAChE)
and human BChE (hBChE), 73% homologous and 54% identical [7], despite the
fact that the enzymes are from species that are very different from the perspec-
tive of evolution. The disulphide bonds in hBChE [8] and TcAChE [9] are in
exactly the same positions, and their three disulphide loops contain exactly the
same number of amino acids. The sequence, GESAG, around the active site S is
conserved, and the lengths of the subunits are similar, 574 for hBChE [10] and
575 for TcAChE [11]. Both proteins are also glycosylated, TcAChE has four
asparagine-linked carbohydrate chains [9] and hBChE has nine [8].
AChE has astonishing catalytic power, the turnover number, k  > 10  s 	
 
, which
is among the highest turnover numbers reported for enzyme catalysis [12]. The






, although AChE also catalyzes reactions of other esters, amides and
anilides [13]. BChE is less active than AChE but also less selective. Both AChE
and BChE hydrolyze different derivatives of pilocarpic acid esters, showing dis-
tinct hydrolysis rates [14, 15, 16, 17].
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2 AIMS OF THE STUDY
Primary purposes of this study was to use theoretical calculations and molecular
modeling to investigate structures and physicochemical properties of small sub-
strates and inhibitors to the two esterases AChE and BChE. Semi-empirical com-
putational methods and molecular mechanics calculations were compared. The
secondary aim of this study was to compare the three-dimensional structures of
AChE and BChE. The specific aims were:
- to compare structural, electronic and electrostatic properties of several deriva-
tives of pilocarpine; the pilocarpic acid esters and the bispilocarpic acid mo-
noesters and diesters.
- to evaluate the requirements for effective enzymatic hydrolysis of the various
pilocarpine prodrugs.
- to get more information about the active site of AChE and BChE by examining
the structural, conformational and electrostatic properties of an inhibitor; bam-
buterol.
- to build a model of BChE by homology modeling and to compare it with the
crystallographic structure of AChE.
- to calculate the relative free binding energies of certain substrates and inhibitors
in the active sites of AChE and BChE, respectively
- to investigate the van der Waals volumes of the substrates and inhibitors of AChE
and BChE
- to get some understanding of why two so closely related enzymes have such
different hydrolysis rates in the case of pilocarpine prodrug molecules and also




Semi-empirical calculations are based on the laws of quantum mechanics, which
state that the energy and other related properties of a molecule can be obtained by
solving the time - independent form of the Schrödinger equation
 (1)
where H is the Hamiltonian for the system,

is the wavefunction and E is the
energy. The Born-Oppenheimer approximation [18] decouples the motion of
the electrons from that of the nuclei giving two separate equations. The semi-
empirical methods solve the equation for the electronic motion like the ab-initio
methods, but they approximate many of the integrals needed with parameters. The
values of the parameters are assigned on the basis of ab-initio calculations or from
experimental data. The semi-empirical methods can be assigned to different cate-
gories on the basis of their level of accuracy. If the parameterization is good, the
calculations provide reasonable qualitative descriptions of the molecular system
and fairly accurate quantitative predictions of energies and structures. The MNDO
[19], AM1 [20] and PM3 [21] methods are parameterizations of the NDDO[19]
model. The improvement of this model compared to the earlier models was among
other things, that the electrostatic properties of lone pairs were now better mod-
eled. The MNDO model was improved by the AM1 and PM3 models but some
limitations still exist. One such limitation is that weak interactions, e.g. hydro-
gen bonds are poorly predicted. Still semi-empirical methods are appropriate for
calculating properties of long series of similar molecules.
In publications I - III and V molecular orbital calculations were performed using
the semi-empirical AM1 [20] method. The PM3 [21] method was used in III.
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3.2 Molecular mechanics methods
Molecular mechanics simulations use the laws of classical physics to predict the
structures and properties of molecules. Each method is characterized by a specific
force field, (FF). In general the energy is written as a sum of terms,
E  = E ﬀ + E ﬁﬀ + E ﬂﬃ + E  !#" + E ﬁ$%ﬁ& + E '(ﬁﬂ (2)
where E ) and E ﬁ*ﬀ are the energy contributions due to bond stretching or com-
pression and angle bending. E ﬂﬃ is the contribution due to torsional alternations,
E  +#" is the energy term due to van der Waals interactions, and E ﬁ$%ﬁ& is an energy
contribution due to electrostatic interactions. E '(ﬁﬂ describes cross-terms or other
special terms, e.g. hydrogen bonding. The methods differ by the complexity of
the potential energy functions used to compute the energy contributions and by
the quality of the force field parameters.
In publications I and II, molecular mechanics calculations were performed using
the FF implemented in the program CHEM-X [22], which is no longer available.
The energy expression consisted of many optional terms, which allowed alterna-
tive functional forms and parameters. At the simplest level, only E ﬀ , E -, (out
of plane bending energy) and a distance restraint energy term E ﬂ were considered.
When more parameters became available E ﬁ) , E ﬂﬃ , E ﬁ$ and a hydrogen bonding
term E '. were included. An advantage of this FF was the possibility of manually
assigning charges on the atoms instead of using the methods by Skorczyk [23] or
Gasteiger and Marsili [24].
In the publications III-V the broadly applicable FFs, such as; the all elements UFF
[25] and the Dreiding FF [26] were used. The bond distortions are described by a
harmonic term or a Morse potential and angle bending by a harmonic cosine term
or a three-term Fourier cosine expansion (UFF). E ﬂﬃ is given as a cosine Fourier
expansion term, E /, is defined according to the Wilson definition [27] (Dreiding)
or as an improper cosine out-of-plane term (UFF). Wilson defines the angle 0 as
the angle between a bond i-j and the plane formed by atoms j-k-l, where i, j, k,
and l are the four atoms in the trigonal center and where the central atom is j.
The van der Waals interactions are described by a Lennard-Jones potential or in
the case of the Dreiding FF also by the exponential-6 form. Atomic monopoles
6
and a distance-dependent Coulombic term describe the electrostatic interactions.
Dreiding FF uses a special hydrogen bond term to describe the interactions in-
volving a hydrogen bond.
The general protein FF CHARMm [28] is also used in the structure optimizations.
The form of the potential energy function differs from the UFF and Dreiding FFs
in that a Urey-Bradley 1,3 distance term is included.
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4 MATERIALS AND METHODS
4.1 Biological background
4.1.1 Pilocarpine
Pilocarpine2 is the main alkaloid obtained from the leaves of the South Ameri-
can shrubs Pilocarpus jaborandi, Pilocarpus microphyllus and other Pilocarpus
species [29]. It occurs naturally as the cis isomer, which is much more potent than
the trans-isomer, isopilocarpine [30]. The action of pilocarpine on the parasym-
phatetic nervous system has been extensively investigated and pilocarpine is act-
ing mainly as a cholinergic agonist.
Despite of several therapeutic effects, pilocarpine is used clinically only to treat
glaucoma [31, 32, 33]. However, pilocarpine presents significant delivery prob-
lems. Its ocular bioavailability is very low. Only 1-3% or less of an instilled
pilocarpine dose gains access to the inner eye structures [34, 35, 36, 37]. If pi-
locarpine gains access to the blood circulation it yields severe cholinergic side
effects, e.g. slowing of the heart, decreasing of the blood pressure and increasing
salivation and sweating [38]. The main reason for the poor bioavailability of pi-
locarpine is its low lipophilicity. Another delivery problem is the short duration
of action. Lowering the intraocular pressure of the eye lasts only for 3 h. These
shortcomings of pilocarpine are dependent on the physiochemical properties of
the drug and may be overcome by the prodrug approach [39].
A successful pilocarpine prodrug should exhibit a high lipophilicity in order to
penetrate through the corneal membrane, but it should also possess sufficient
aqueous solubility and stability for eyedrop formulations. Moreover, the pilo-
carpine prodrug should be converted to the active parent drug within the cornea
and a controlled release of the drug should take place.
2The structure of pilocarpine is depicted in Fig.3.
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4.1.2 Bambuterol
The prodrug approach led to the discovery of bambuterol, a bis-N,N - dimethyl-
carbamate of terbutaline, displaying improved hydrolytic stability, high bioavail-
ability and long duration of action [40]. Bambuterol is a selective inhibitor -
acting as a substrate of slow turnover - of BChE with an IC 1#2 of 17 nM, while
the corresponding value for AChE is 41 3 M [41]. The monocarbamate is the in-
termediate in the hydrolysis reaction. Moreover, bambuterol acts like a double
prodrug, since an oxidative metabolism also takes place generating new lipophilic
N-demethylated derivatives, which spontaneously decompose to terbutaline [42].
In Figure 1 the pathway from bambuterol (1) to terbutaline (3) is shown, together








































R = CH(OH)CH2NHC 33(CH  )
Fig.1 Structural formulas of bambuterol (1), the monocarbamate (2) and terbu-
taline (3), together with some of the metabolic intermediates; the hydrox-




AChE is one of the most efficient enzymes from the family of serine hydrolases,
operating at a rate approaching the diffusional limit [43, 44, 45]. The X-ray crys-
tallographic structure of TcAChE [46], showed that the enzyme contains the cat-
alytic triad, E327, H440, S200 in a mirror image relationship to that present in
other serine hydrolases. The triad is located at the bottom of a narrow, 20 Å deep
gorge. The mechanism of the hydrolytic reaction catalysed by serine proteases is
outlined in Figure 2 in the case of an ester substrate. The reaction scheme is also
a probable mechanism for AChE and BChE hydrolysis, where the amino acid D
is replaced by E. The OH-group of S200 is rendered more nucleophilic through
the proton-acceptor role of amino acid H and is then capable of executing a nu-
cleophilic attack on the carbonyl carbon of the ester substrate. First, a tetrahedral
transition state is formed, then the amino acid H is deprotonated as the alcoholic
part of the ester is leaving. The next step in the hydrolysis is a base catalysed
reaction involving a water molecule.
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Fig.2 Proposed mechanism of the hydrolytic reaction catalysed by serine pro-
teases (Asp) or cholinesterases (Glu) [47].
Compounds that block AChE thereby inhibiting the destruction of released acetyl-
choline are called anticholinesterase drugs. Acetylcholinesterase inhibitors can
act by two different mechanisms. They have a high affinity for the active site,
occupying it for a relatively long time and acetylcholine cannot be hydrolyzed as
a result of this saturation phenomenon. Alternatively the inhibitor acylates the
OH-group of S200, forming a more stable ester than acetate. Hydrolysis of such
carbamate- or phosphate esters takes a long time, polyalkylphosphate esters, e.g.
nervgases are bound irreversibly and are very toxic. The active site is covalently
occupied and acetylcholine cannot be hydrolyzed.
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4.2 Computational methods
4.2.1 Molecular modeling (I-V)
Molecular modeling and all molecular mechanics calculations (I, II) were per-
formed with the aid of the CHEM-X software [48] installed on a VAX 8650
computer at the Finnish Center for Scientific Computing (CSC). The molecular
mechanics energy minimization was continued until the conformational energy
remained constant during several iterations and stopped when the default energy
convergence criterion 1.0 4 10 	5 kcal/mol was reached. Convergence in the mini-
mizer is determined by the energy difference between successive cycles. Confor-
mational search of the pilocarpic acid diester compounds was done by varying the
torsional angles of the R   and R  side chains (I, Table 1).
The QUANTA software [49], the CHARMm program [28] as implemented in the
QUANTA program package and the CERIUS software [50] were used for molec-
ular modeling and molecular mechanics calculations in (III-V). The molecular
modeling and all calculations were done using the Silicon Graphics 4D/300 series
workstation and an O2 workstation. The computers Cypress2 and Cedar, main-
tained by the CSC were also used.
The semiempirical MO structure calculations were done with the AM1 method
[20] (I-III, V) and the PM3 method [21] (III) implemented in the AMPAC [51] or
MOPAC [52] program packages. The computers used for these calculations were
the CSC VAX 8650 and the CSC Cray X-MP EA/432 computers (I-II) together
with the Silicon Graphics 4D/300 workstation (III). The semiempirical geometry
optimizations were performed with the keyword PRECISE (III). In the studies
of pilocarpic acid diesters (I) and the bispilocarpic acid diesters (II) the keyword
PRECISE was not employed because of the size of the molecules.
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4.2.2 Comparative modeling (IV)
Comparative modeling or homology modeling is applicable where the target pro-
tein sequence, is found to be significantly related to that of one or more known
structures. The folds of the proteins are approximately the same, with greater sim-
ilarity at greater sequence identity [53]. The amino acid sequence of TcAChE and
hBChE is 73% homologous and 54% identical [5].
The first step in comparative modeling is to identify the known three-dimensional
structures that will form the basis for the structure of the unknown protein. Then
alignment of the target structure on the backbone of the parent structure takes
place. Differing sequence lengths makes it a nontrivial task. Structure fragments,
which are similar enough in conformation to the target protein are selected and
side chains are built in. Short regions of the chain usually remain unbuilt e.g.
loops, due to incorrect positions of the root residues. When the chain is complete,
energy minimization is used to refine the model. Twenty selected protein chain
fragments from the Brookhaven Protein databank (PDB) [54] were inserted in the
model of hBChE for the structural variable regions (IV).
The program MODELLER [55] can be used in all stages of typical comparative
modeling by using suitable template structures in the PDB and aligning them with
the sequence to be modeled. A three-dimensional homology model of hBChE
(IV) was built by the program with the TcAChE structure as the template structure.
4.2.3 ONIOM (V)
The ONIOM module, [56] as implemented in the GAUSSIAN 98 program pack-
age [57] is a multilayered integrated MO + MM method for geometry optimiza-
tions and single point energy calculations. In my investigations the system was
divided into two layers. The active part of the system, which consisted of the sub-
strate or the inhibitor molecule, the triad of the active amino acids and all residues
within a radius of 5 Å from the O-atom in the group of the active amino acid S,
was treated at a semiempirical level with the AM1 method [20]. The radius of 5
Å was chosen because of the preferable dimensions of the inner layer. The AM1
calculations comprised about 250 atoms, a radius of 6 Å would have increased the
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number of atoms in the inner layer by approximately 75. The rest of the esterase
was treated using molecular mechanic calculations. The connecting bond lengths
between the two layers were frozen, the bond and dihedral angles were assumed
to be the same for all connections and the connecting atoms in the lower layer
were replaced with hydrogens in the higher layer.
4.2.4 Ligand_Design (V)
The Ligand_Design module, an interface to the software Ludi [58], was used to
study scoring functions between the substrates, alternatively the inhibitors and
the esterases. The number and quality of the receptor-fragment hydrogen bond
and the receptor-fragment hydrophobic contact area were also calculated. In this
study the Insight II program [59] was used because the Ligand_Design module is
accessible through that program.
14
5 RESULTS AND DISCUSSION
5.1 Modeling of pilocarpine (I)
The structure of pilocarpine was proposed by Jowett in 1900 [60] and subse-
quently confirmed by X-ray analyses [61, 62]. The ethyl- and imidazolylmethyl
groups on the dihydrofuranone ring are cis, making the configurations at these
carbons R and S, respectively. The AM1 and MM optimized structures were in
good agreement with one of the experimental structure, see Figure 1 in publication
I. The lactone ring was used as a superposition template. The largest structural
difference was found for the dihedral angle between the imidazole and the lactone








Fig.3 The structural formula of pilocarpine.
The conformation of pilocarpine is largely defined by the values of the three tor-
sion angles 6 , 7 and 8 . The conformational energy of pilocarpine was obtained
by AM1 calculations and performed on a 30  grid of 6 - 7 values. For every
6 - 7 pair, the remaining structure was freely optimized. Three local energy
minima were found, where 9 H : < -44.0 kcal/mol. Another study of the con-
formational potential energy surface of pilocarpine by Schulman et al. [63] lo-
cated six minima, four nearly equienergetic minima and two somewhat higher in
energy. The crystal structures of pilocarpine-trichlorogermanate(II)hemihydrate,
(C  #  H  ; N  O  ,GeCl < ,   H  O) [61] and pilocarpine hydrochloride, (C  #  H  ; N  O  ,Cl)
[62] were determined by X-ray crystallography. A comparison of the experimen-
tal and calculated 6 -, 7 - and 8 -torsion angles, is seen in Table 1.
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Table 1. Torsion angles (  ) and standard heats of formation (kcal/mol) of
different conformers of pilocarpine.
Method 6 7 8 9 H :
exp. data [61] 7.4 71.7 64.4
exp. data [61] 18.2 72.3 58.4
exp. data [62] -4.2 168.4 -171.4
1) MM 40.7 60.1 87.2
1) AM1 35.3 76.4 98.1 -44.5
2) AM1 78.2 134.1 92.9 -44.7
3) AM1 64.2 68.3 82.8 -45.4
1) = AM1 [63] 64.2 68.0 81.2 -45.4
2) = AM1 [63] >@? -107.0 66.2 81.0 -45.5
3) = AM1 [63] 3.9 162.4 171.3 -44.8
4) = AM1 [63] 117.2 163.7 172.9 -45.2
>? global minimum
The value of the experimentally determined 6 -torsion angle is very different from
most of the calculated values. The values of the 7 - and 8 -torsion angles may
roughly be divided into two groups. The 3) and the 1) = minimum coincide. On the
other hand the global minimum 2) = was not found.
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5.2 Modeling of pilocarpic acid esters (I)
The template structure of the pilocarpic acid esters investigated is seen in Figure
4. The different R   and R  substituents are collected in Table 1 in publication I.
In addition to the diester compounds, the corresponding monoesters, in which the















Fig.4 The template structure of the pilocarpic acid diester compounds.
The first task was to get reasonable molecular structures of the pilocarpine prodrug
molecules, because no experimentally determined structures were available. The
calculated AM1 and MM structures of the diesters were quite similar. A complete
conformational search of all bonds in the molecules was not performed, because
of the size of the molecules. However, the conformational space of the side chains
R   and R  was thoroughly searched. The energy barriers were small in the internal
movements of the side chains, and many energetically close conformations were
found. In Table 2 the number of conformations within 3 kcal/mol are given for
some pilocarpic acid diester compounds, which are denoted as B or K, depending
upon whether they were introduced by Bundgaard and co-workers (B) or by the
Kuopio group (K) (I) [64].
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Table 2. Number of conformations, within 3 kcal/mol for some pilocarpic
acid diesters.
B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 K5 K6
5 9 5 3 4 4 2 6 6 5 7 7
In Table 2 it is seen that only two low energy conformations are found for the
diester B7, where the R  is a t-butyl group. It is interesting to note that diester
B7 is very stable to enzymatic hydrolysis. The reported half-life (t   ) is 330 min.
(see Table 1 in publication I). The slow hydrolysis may partly be a result of the
steric hindrance by the t-butyl group. The diester B2 is conformatically flexible
and the hydrolysis is very fast, the t   is 4 min. Protonating the molecules at the
imino N in the imidazole ring did not generally change the bond distances and
bond angles of the side chains although some small changes could be observed.
The angle for the R  side chain, N - C(carbonyl) - C(end) showed greater variation
upon protonation than the corresponding angle for the R   side chain. The esterase
hydrolysis affects only the R  side chain of the diester.
The pilocarpic acid monoesters did not show as much structural differences as did
the corresponding diester compounds.
The pilocarpic acid diesters showed very different values of t   in the esteratic
hydrolysis. All diesters with t   < 10 min were selected as fast regarding en-
zymatic hydrolysis. The corresponding t   for the slow diesters was > 70 min.
From Figure 5a it is seen that the spatial requirements for the compounds exhibit-
ing a fast enzymatic process differ markedly from those shown in Figure 5b. The
spatial extent of the superposition in Figure 5a resembles a bold T, with the ethyl




Fig.5 Superimpositions of low-energy conformers of the diesters with t   < 10
min in human plasma or serum solution (a) and in (b) the diesters with t  
> 70 min.
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The absence of an X-ray structure of BChE lead to the empirical approach to
make an active-site model for interpreting and predicting the specificity of both
AChE and BChE. The catalytically active amino acid S was placed in a fixed
position in space and the hydrolyzable ester group of all pilocarpic acid ester
molecules was placed in the serine nucleophilic region. The remaining parts of the
substrates were superimposed to get the common occupied volume. The substrate
atoms are studied as point-like, no van der Waals radii are considered. Thus the
actual volumes of the model are somewhat larger. The hypothetical active-site
model that emerged is shown in Figure 6. Nevertheless this model is based on one
selected pharmacophore, conformation and orientation of the substrate, indicating















Fig.6 Active-site model of the cholinesterases. The active amino acid serine is
encircled and the length unit is in Å. The imidazole-, carbonyl- and ethyl-
fragments of the pilocarpic acid structure are placed in the model.
This active-site model of the cholinesterases resembles the active-site model [65]
of pig liver esterase (PLE, E.C 3.1.1.1).
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5.3 Modeling of bispilocarpic acid diesters (II)
Bispilocarpic acid diesters constitute a new class of pilocarpine prodrugs and they
can be divided into two class of compounds; bispilocarpic acid monoesters and
bispilocarpic acid diesters, depending on the different aliphatic or aromatic link-
ages or spacers between the two pilocarpic acid moieties. These prodrug deriva-
tives have been synthesized and thoroughly investigated by Järvinen et al. in the
Kuopio group [2]. Physicochemical properties such as lipophilicity and aqueous
stability were generally improved for these double prodrugs in comparison with
the pilocarpic acid mono- and diesters. The template structures of the bispilo-
carpic acid monoesters and the bispilocarpic acid diesters are shown in Figure 7.


























































Fig.7 The template structures of bispilocarpic acid monoesters (a), and the bispi-
locarpic acid diesters, which include O,O’-dicarboxylate bispilocarpates (b)
and O,O’-1,4-xylylene bispilocarpic acid diesters (c).
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The calculated AM1 structures of the pilocarpic acid diesters (I) were used for the
initial geometries of the bispilocarpic acid diesters. The results of the conforma-
tional analysis were found to be in accordance with those found for the pilocarpic
acid diesters (I). A similar superposition study as for the pilocarpic acid diesters
was done. Those biscompounds, which hydrolyze rapidly, t  BA 15 min have a
very compact, almost symmetric structure, see Figure 8a. The shape resembles
not one single T, but two T’s with a common, joined base of stems. The superim-
position shape of the slowly hydrolyzed, t  DC 150 min, compounds in Figure 8b




Fig.8 Superimposition of the biscompounds selected as undergoing (a) rapid and
(b) slow hydrolysis. Superimposition along respective spacer or linkage
atoms.
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The intramolecular N to N’ distances between the imino N atoms in the two im-
idazole rings were measured, (II). This distance varies from 5.9 to 20.6 Å. On
average, the N to N’ distance of all biscompounds, which undergo fast enzy-
matic hydrolysis, is 18.6 Å, whereas the corresponding distance for the slowly
hydrolyzed compounds is only 15.0 Å. Decamethonium, which contains two qua-
ternary trimethylammonium groups connected by ten methylene units, triggers
the same response as does acetylcholine, i.e., a brief contraction of the muscle.
However, this response is followed by a long period of muscular paralysis [66].
The intramolecular N E - N = E distance has theoretically and experimentally been
determined to lie between 9.5 and 13.5 Å [66]. As the number of atoms between
the two nitrogen containing groups is increased beyond ten, the activity decreases
until a second peak is reached for a distance of about 20 Å between the nitro-
gens, a value resembling the intramolecular distance of about 18.6 Å for those
biscompounds that hydrolyze rapidly.
5.4 Comparative model building of hBChE (IV)
Comparative modeling or homology modeling is a general method to build three
dimensional models of proteins for which crystal structures of other proteins in
the same family are known [67, 68]. The molecular model of the three dimen-
sional structure may explain the structural basis of existing experimental results
and could provide some information on what type of further experiments should
be planned, executed and evaluated. Although the complete amino acid sequence
of hBChE has been determined [69], the three dimensional structure, is not yet
known.
A computer model of hBChE was constructed starting from the coordinates of
TcAChE at 2.8 Å resolution [46]. Residues 4-534 of TcAChE were successfully
aligned with residues 2-532 of hBChE with no deletions or additions. The missing
residues 483-487, TQNNS, in the loop were modeled on a fragment obtained
from a PDB search. The last amino acids 533-574 were not built into the model,
because they were deemed to be insignificant for the investigation of the active
site. Twenty selected fragments (Table 1, IV) from the PDB were inserted for
the structural variable regions in the hBChE model. To compare the result of the
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comparative modeling the MODELLER program was used to build a model of
hBChE. Hydrogen atoms were added to the BChE models in standard geometries,
before energy minimization. Earlier modeling studies have shown that the overall
features of the modeled BChE structure closely resemble those of AChE [70, 71].
A comparison of TcAChE and the two models of BChE is seen in Figure 9.
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Fig.9 Superimposition of TcAChE (refined structure)(—), BChE (homology model)
(—) and BChE (generated by MODELLER)(- -). The structures are dis-
played as C F -traces and the amino acid coding refers to the TcAChE.
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All the 6 -helices and 7 -strands are quite well conserved, as is the active site re-
gion. The loop, consisting of the residues 485-489, (the numbering referring to
TcAChE) shows the largest variation. In general the active center of cholinesterases
lies in the center of a globular shaped molecule. The catalytic triad, E327, H440,
S200, in TcAChE is located near the bottom of a 20 Å deep narrow gorge. The
walls of this gorge consist mainly of multiple layers of amino acids. However,
one wall is formed by the loop C67 - C94 and is only one residue thick.
5.5 Structural similarities and differences of AChE and BChE
(IV, V)
In the BChE model a similar channel as in TcAChE leading to the active site
was found, but it was not as narrow and it did not contain as many aromatic
amino acids as the channel found in TcAChE. Different studies of the active site
in TcAChE have revealed two major subsites, located at the bottom of the deep
gorge. One is the catalytic triad, consisting of E327, H440, S200, and the other
is the “anionic” subsite or quaternary ammonium binding locus, where the amino
acid W84 plays an important role, because of G - G interaction [72]. In BChE the
corresponding amino acids are E325, H438 and S198 for the catalytic triad and
the most important amino acid in the quaternary ammonium binding site is W82.
The void space of the active center in BChE is greater than in AChE, allowing
the substrate or inhibitor to move more freely. Recent studies of hAChE and the
hexamutant hAChE, where six aromatic residues in the active site were replaced
by aliphatic ones, showed that the hexamutant hAChE had a similar reactivity
as hBChE toward some inhibitors, e.g. tacrine, decamethonium and huperzine
A [73]. These results support the accepted view that the active center of AChE
and BChE differ mainly by the presence of a larger cavity in BChE. Neverthe-
less, reactivity of the hexamutant hAChE toward the substrates acetylthiocholine,
butyrylthiocholine and TMTFA is lower than that of hBChE [73].
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Two other sites in TcAChE are also found, an oxyanion hole formed by the pep-
tidic NH functions of the amino acids G118, G119 and A201 and an acyl binding
pocket including the amino acids W233, F288, F290, F331 and G119 [74]. An-
other anionic subsite, a peripheral one (PAS) is found in TcAChE near the top of
the gorge leading to the active site. Inhibitors, such as E2020 and decamethonium
and probably also substrates with aromatic rings and charged nitrogens interact by
classical G - G interaction [72] with the amino acid W279. The snake venom fas-
ciculin, a 61-residue polypeptide, selectively inhibits TcAChE by binding at this
peripheral site [75]. BChE lacks this specific tryptophan residue at this position
and if a distinct peripheral anionic site exists in BChE, it is structurally different
from the one found in AChE. In addition, the possible difference in the location
of the PAS sites may be related to the finding that modulation of catalytic activity
at high substrate concentrations, which is thought to involve substrate binding at
the periphery, appears to be different for AChE and BChE, leading to substrate
inhibition in AChE [76] and substrate activation in BChE [77, 78].
Another peripheral anionic subsite in TcAChE at the midpoint of gorge has been
discussed. The amino acid F330 is involved in G - G interactions and this amino
acid is also thought to act like a “swinging gate”, when adopting a wide range of
different conformations [79].
In BChE the oxyanion hole is formed by the peptidic NH functions of the amino
acids G116, G117 and A199. The acyl binding pocket of BChE is somewhat
different from TcAChE, the constricting amino acids F288 and F290 [74] are re-
placed by L286 and V288 in BChE, allowing bigger substrates to be hydrolyzed.
The internal disulfide bridges in BChE are in exactly the same positions and their
loops contain exactly the same number of amino acids as in AChE.
The existence of a “back door” mechanism in AChE has been disputed. A molec-
ular dynamics simulation of TcAChE in water reveals the transient opening of a
short channel, large enough to pass a water molecule, trough a thin wall of the
active site near W84 [80]. This simulation suggests that substrates, products or
solvent molecules could move through this “back door”, in addition to the en-
trance of the gorge. Another study with hAChE mutants, where the turnover rates
were measured, strongly suggests that the “back door” is not a route for clearance
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for the enzymatic reaction products [81]. Nevertheless, one could speculate that
binding of a substrate to the active center induces an allosteric effect that opens
the gorge and thus facilitates product release. However, a recent crystallographic
study of a complex between TcAChE and a physostigmine-like inhibitor, MF268,
showed that the alkyl chain of the inhibitor filled the upper part of the gorge,
blocking the entrance of the active site [82]. Surprisingly, the relative bulky leav-
ing group, eseroline, was not found in the crystal structure, thus implying the
existence of an alternative route for its clearance [82].
A similar “back door” has not been discovered in BChE , at least to the best of my
knowledge.
5.6 Selected substrates and inhibitors interacting with
TcAChE and BChE (IV, V)
The establishment and reorganization of specific covalent or noncovalent interac-
tions between substrates or inhibitors and the two macromolecules AChE and
BChE are very important and play a crucial role in the their biological func-
tion. There is a steric complementarity as well as electrostatic interactions be-
tween the substrate and the esterase. Crystallographic structures of substrate
(inhibitor) -TcAChE complexes are available [46, 74, 83] and the coordinates
were imported from the PDB [54]. The molecular formulas of the selected sub-
strates and inhibitors are seen in Figure 10. Acetylcholine from the X-ray struc-
ture of TcAChE was used as a superposition template for the substrates; butyryl-
choline, the bispilocarpic acid diester C6 and for the inhibitors bambuterol and m-
(N,N,N-trimethylammonio)-2,2,2-trifluoroacetophenone (TMTFA) when no crys-
tallographic data was available from PDB. The homology built model of hBChE
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Fig.10 Molecular formulas of the substrates; acetylcholine (1), butyrylcholine
(2), O,O’-1,4-xylene bispilocarpic acid diester C6 (3) and the inhibitors;




Hydrogen bonds are among the most important interactions between molecules.
Optimal hydrogen bonds are linear, whereas bent hydrogen bonds are weaker,
suggesting that the geometric arrangement of the involving atoms is important.
Instantaneous intermolecular recognition in many biological processes operates
with hydrogen bonds, which allows very fast association and dissociation of small
molecules with macromolecules [84].
Intramolecular hydrogen bonding between the active amino acids E327 (E325),
H440 (H438) and S200 (S198) in the active site of TcAChE and BChE (IV) was
studied. As a result of distance measurements, two good hydrogen bonds can
be formed in the active site of AChE and only one in BChE, indicating perhaps
a more rigid active site structure in AChE than in BChE. Recent NMR studies
suggest a short, strong hydrogen bond (SSHB) between the amino acids E and H
of the catalytic triad in horse BChE [85]. The length of a normal weak hydrogen
bond is 2.75 to 3 Å, whereas the length of a linear SSHB varies from 2.45 to 2.65
Å and if bent it is even shorter. From Table 3 in publication IV the length of
this particular hydrogen bond is 2.11 and 2.01 Å for the two molecular models of
hBChE. This SSHB has the ability to increase the basicity of the amino acid H,
permitting it to deprotonate the catalytic S, which is one of the first steps in the
enzymatic hydrolysis reaction of the esterases.
Intermolecular hydrogen bonding, a hydrogen bond between the substrates (in-
hibitors) and the esterases was studied using the Ligand_Design module [59], see
Table 3 in publication V. The two substrates acetylcholine and butyrylcholine in-
teract with two hydrogen bonds each. The other substrate O,O’-1,4-xylene bispi-
locarpic acid diester C6 interacts differently in the active site. Nine hydrogen
bonds are formed in the active site of AChE and six in the case of BChE. This
may be another indication why BChE hydrolyzes this substrate more readily than
AChE, the hydrolysis rate is nearly 500 times faster as compared to AChE hy-
drolysis. [86]. The transition state analog TMTFA forms three hydrogen bonds in
the active site of AChE, as was reported by Harel et al. [77], no hydrogen bonds
are formed within the active site of BChE. The inhibitor bambuterol interacts with
more hydrogen bonds than TMTFA in the active site of BChE; ten hydrogen bonds
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are formed. This strong interaction correlates well with the fact that bambuterol
has a high affinity for BChE in comparison of AChE [41].
5.6.2 Van der Waals volumes (IV, V)
The union of the overlapping atomic van der Waals spheres is called the van der
Waals volume of the molecule and this volume can be used when comparing the
shapes of similar molecules. Van der Waals volumes of the superimposed sub-
strates and inhibitors in the active sites of the two esterases were calculated, using
acetylcholine from the crystallographic structure of TcAChE [46] as a superim-
position template. The grid resolution was 0.5 Å. Table 4 in publication IV gives
the total molecular volume, the intersection volume and the union volume with a
selected target molecule, acetylcholine for AChE and butyrylcholine for BChE,
respectively. In Table 3 some new van der Waals volumes of the substrates and
inhibitors as a group are reported.
Table 3. Molecular volume (Å < ) of different substrates and inhibitors as a group,
their superimposed intersection (and) and common (or) volumes.
AChE BChE
substrates; acetylcholine/butyrylcholine and bispilocarpic acid diester C6 67.5 124.2
inhibitors; bambuterol and TMTFA 120.4 90.2
substrates; acetylcholine/butyrylcholine or bispilocarpic acid diester C6 (1) 732.8 760.5
inhibitors; bambuterol or TMTFA (2) 421.8 503.5
inhibitors and not substrates (2-1) 201.2 252.4
substrates and not inhibitors (1-2) 512.1 509.4
substrates and inhibitors (1+2) 220.6 251.1
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Table 3 shows that the total intersection volume of all substrates takes a smaller
volume in the case of AChE compared to BChE, 67.5 Å < and 124.2 Å < , respec-
tively. This indicates that the active site of AChE is smaller and perhaps more
rigid in comparison to the active site of BChE. In fact, volume calculations of the
active site gorge of BChE showed that it is about 200 Å < larger than that of AChE
[87]. The opposite is found in the case of the intersection volume of the inhibitors.
The total volume in common for the substrates, 732.8 Å < in the case of AChE and
760.5 Å < for BChE, also indicates that the active site of BChE is greater than the
active site of AChE. The total volume shared of all the substrates and inhibitors
implies the same trend.
5.6.3 Relative free energies (V)
No generally satisfactory solution exists for the difficult problem of calculating
ligand-protein binding affinities. The binding affinity or absolute binding free
energy is calculated from the free energy of the ligand-protein complex subtracted
by the terms of the individual free energies of the ligand and the protein in aqueous
solution. Alternatively, the relative binding free energy ( 9 ( 9 G  ) of two related
proteins, in this case the enzymes AChE and BChE, to a substrate or inhibitor
molecule was considered.
9IH9 G  ) = [G(S/I E  )-G(S/I E   )]+[G(E   )-G(E  )] (3)
The double subtraction may cause a nearly complete cancellation of errors, re-
sulting in fairly good values of ( 9 ( 9 G  )). The binding of acetylcholine, butyryl-
choline, O,O’-1,4-xylene bispilocarpic acid diester C6, bambuterol and TMTFA
to the two esterases was investigated. Acetylcholine from the X-ray structure of
TcAChE, again, was used as a superimposition template for the substrates when
no crystallographic data was available from PDB. Before the ONIOM calcula-
tions, MM calculations were done until the RMS force value was A 0.1 kcal/mol
Å. Table 2 in publication V shows the ONIOM extrapolated energy and the calcu-
lated change in relative binding energy, 9 ( 9 G  ) in kcal/mol. Equation (3) is used
to calculate the 9 ( 9 G  ) values, E  is defined as AChE and BChE is E   .
In this case a positive 9 ( 9 G  ) value indicates that the binding is unfavorable to
AChE in comparison to BChE and most of the 9 ( 9 G  ) values are positive. The
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negative 9 ( 9 G  ) value, -0.17, for the O,O’-1,4-xylene bispilocarpic acid diester
C6 signifies a stronger binding to AChE as compared to BChE, which may be one
explanation for the slower hydrolysis rate in the case of AChE [86].
It must be emphasized that studying relative binding free energies in this way is a
very qualitative exercise. Quantitative accurate relative binding energies can only
be achieved when solvent effects are included and computational procedures are
improved.
5.7 Electrostatic and electronic properties (I - III, V)
The electronic structure - the arrangement, nature, and interaction of electrons in
the molecule - is essential for the chemical reactivity of that molecule. TcAChE,
hBChE and other cholinesterases seem to have an asymmetric charge distribu-
tion, such that there is an excess of negative charge in the region near the gorge
entrance, relative to the other side of the enzyme [88]. The negative potential
near the rim may play a significant role in accelerating diffusion of an cationic
substrate toward the active site. The negative potential in the gorge of TcAChE
increases gradually as one goes down the gorge and reaches a maximum near its
base [88, 89]. Tan et al. showed that the potential is positive on the side opposite
the active site of TcAChE [90], leading to the proposed mechanism that if a pos-
itively charged substrate approach this side, it is repelled and then steered toward
the active site.
The atomic charges of the pilocarpic acid diesters (I) were calculated using the
AM1 [20], the Skorczyk [23] and Gasteiger [24] methods and the corresponding
molecular electrostatic potential (MEP) at van der Waals surface was constructed.
The VSS method of Giessner-Prettre [91] was also used for a MEP calculation.
All MEPs of the diester B1 are shown in Figure 5 in publication I. Large negative
areas are found associated with the imidazole fragment and both ester linkages,
a smaller negative region is found on both sides of the R   phenyl ring plane. A
definitive positive area is found for the imidazole methyl group, the ethyl group
and the aliphatic R  side chain. The MEPs of the remaining diesters were very
comparable to the MEP of the B1 compound, a fact indicating that electrostatic
differences alone between the different compounds could not explain their differ-
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ent reactivities in the enzymatic hydrolysis reaction.
The MEPs of the bispilocarpic acid monoesters and the bispilocarpic acid diesters
were also studied. A superposition of the rapidly hydrolyzed bisprodrugs were
made and their MEP showed markedly larger connected negative fields around
the imidazole fragment and a positive region close to the active ester group. The
compounds, which are hydrolyzed slowly, did not show as well-defined negative
and positive regions as the rapidly hydrolyzed prodrugs.
The molecular electrostatic potential of the inhibitor bambuterol was also studied
(III). The calculated MEP, using AM1 charges showed that a negative region is
found around the central part of the molecule.
The characterization of a molecular electrostatic potential is important to discover
factors, which affect stabilization of a substrate (inhibitor)-enzyme complex, but
with the consideration that different charge calculation methods give very different
results. In addition, this study of MEPs showed that the molecular structures of the
substrates were not different enough to obtain very distinct and individual MEPs.
The different hydrolysis rates of the studied substrates and inhibitors cannot be
explained only by the electrostatic potential, although it is very important. Steric
effects in this kind of hydrolysis reactions may even be more important.
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6 CONCLUSIONS
MM and AM1 molecular structures for a series of pilocarpine prodrug molecules
of several types were compared. The calculations showed that the MM structures
are of comparable quality with the AM1 structures in the majority of cases.
The requirements for effective interaction with the hydrolyzing esterase enzyme
indicates that prodrug molecules which attain a T-shaped or double T-shaped
structure should best fit in the active site.
The MEPs of the substrates and the inhibitor bambuterol did not show enough dif-
ferences to account for the different hydrolysis rates of the studied substrates and
inhibitors. The MEPs depend on the calculation method, considerably differences
are found between the AM1, PM3 and MNDO charges (publication III).
A reasonable model of hBChE was built by homology modeling and it remains
useful until the X-ray structure is solved. In BChE a similar channel as in AChE
leading to the active site was found, although it was not as narrow as in AChE.
The channel did not contain as many aromatic residues as the one in AChE. The
active site of BChE is greater than AChE, allowing bulky substrates to undergo
enzymatic hydrolysis. The peptide bond of the active amino acid S became more
polarized when a substrate or inhibitor is bound in the active site of AChE than in
BChE. The O-atom in the OH-group of the active amino acid S shows a different
charge distribution in AChE and BChE. In AChE the negative charge decreases as
the substrate binds, and decreases even more when an inhibitor binds. In BChE
the charge adopts two values regardless of substrate or inhibitor binding. If a
distinct peripheral anionic site exists in BChE, it is structurally different from the
one found in AChE.
The study of the van der Waals volumes of the substrates and inhibitors of AChE
and BChE in the active site indicated that the active site of AChE is smaller and
perhaps more rigid in comparison to the active site of BChE. It was also seen
that bambuterol has a smaller molecular volume in the active center of AChE as
compared to the corresponding volume in BChE. The smaller molecular volume
perhaps suggests that bambuterol is forced into an energetically unfavorable con-
formation, which may help to explain the different affinities of bambuterol for the
36
two esterases.
Water molecules play a significant role in the interactions of substrates (inhibitors)
in the active site in the hydrolysis of these molecules and further studies including
water molecules in the active site are presently under consideration [92].
The molecular recognition of substrate (inhibitor)-enzyme structures is highly
complex, and our understanding of these equilibrium processes still remain rather
elementary. Molecular dynamics simulations can provide us with valuable in-
formation about these substrate (inhibitor)-enzyme complexes by investigating
the stability of the complexes and examining the occurrence of local structural
changes in the residues forming the active site.
Finally, it is very important to compare all calculated data with experimental data,
when such data is available.
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